Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Amyloid Receptor and Inhibitor for AD Pathology_Seoul National Univ.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Amyloid receptor and inhibitor for AD pathology...
Contact Yong U Kim
Participants
You
Email me a copy of this message

1. Background of Technology


1.1. Amyloid hypothesis in Alzheimer's disease


- Clinical association of amyloid42 oligomers with Alzheimer's disease


: Detection of amyloid42 oligomers in the brain of AD patients


: Apparent evidence for the role of amyloid42 oligomer in AD Pathology


           : High ratio of Amyloid 42/40 for pathology


 


1.2. Amyloid42 receptors: not successful yet


- RAGE (Nature 1996)


          : Role in amyloid transport in BBB (2008, 2009, ICAD)


          : However, a role in the memory impairment of AD is not clear


- ABAD (Science 2005)


          : Role in mitochondria for amyloid toxicity


          : However, a role of ABAD in the memory impairment of AD is not clear


-Prion (Nature 2009) etc.


          : Role in LPT


          : However, a role in the memory impairment of AD is not clear yet.


 


1.3. Limited available targets in the amyloid pathology for drug development in AD


- Beta, gamma secretases are good targets but development of inhibitors have problems.


          : Gamma-secretase: too many substrates  


: Beta secretase: Difficulty to design inhibitor in brain


-Aggregation blockers, amyloid antibody etc


          : Long history, being tried by many groups.


 


1,4.  Looking for New therapeutic targets


 -Additional new targets are needed.


 


2. Description on Technology Applied


2.1. Amyloid 42-binding receptor (AIMP) discovered


-Interaction was confirmed in in vitro and cell level


-Amyloid42-selective interaction (Amyloid40 not bound))


-Monomer and oligomeric forms of amyloid42 bind to AIMP receptor


-Binding region was identified by in silico modeling and by mutagenesis


2.2. Role of the amyloid receptor in amyloid pathogenesis


-Increased expression of AIMP in the brains of AD and APP moce


-Essential role of AIMP receptor in neurotoxicity and Tau phosphorylation in cultured neuronal cells


-Inhibition of amyloid42-induced memory impairment in AIMP receptor KO mice (icv injection)


-No reduction in amyloid42-induced LTP in the brain of AIMP receptor KO mice.


-AIMP KO/PDAPP double transgenic mice rescue memory impairment of PDAPP mice.


-There is another ligand for the receptor and thus, selective inhibition is required to avoid unwanted effects.


 


2.3. Small compound inhibitor (inhibitor X) against amyloid receptor:


-AIMP inhibitor compound Isolated from in silico modeling


          : Using in silico-modeling of the receptor and amyoid42, one million compounds were screened.


- In vitro, in vivo effects: Inhibition of receptor-mediated memory impairments


          : AIMP inhibitor inhibits the interaction of amyloid42 with AIMP


          : AIMP inhibitor inhibits amyloid42-induced neuronal toxicity in vitro


          : AIMP inhibitor inhibits amyloid42-induced memory impairment (memory test after amyloid42 i.c.v. injection).


          : AIMP plays a role in neuronal transport of amyloid42


          : Being tested for BBB transport.


 


Taken together, these in vitro and  in vivo analysis of AIMP and its inhibitor provide a proof of concept that AIMP may serve as a receptor of amyloid42 (Fig. 1)

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
US9234038B2, US8124358B2, EP2268296B1, PCT/KR2008/006570
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE